Oncology Learning Network

🚨 Breaking: The @US_FDA has approved #gedatolisib plus #fulvestrant, with or without #palbociclib, for patients with #PIK3CA wild-type, HR-positive, #HER2-negative advanced or metastatic breast cancer following prior endocrine therapy. Learn more: hmpgloballearningnetwork.com/site/onc/fda-a…

Results from the phase 2 #DURABLE trial: Maintenance #durvalumab plus #anlotinib improved #PFS following first-line #chemoimmunotherapy in extensive-stage #SCLC, supporting further evaluation of this maintenance strategy. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

🚨 Breaking: The @US_FDA has approved #selpercatinib for adults and children with locally advanced or metastatic #RET fusion-positive solid tumors, reinforcing its role as a tissue-agnostic treatment option. Learn more: hmpgloballearningnetwork.com/site/onc/fda-a… #onctwitter #medtwitter

Results from a phase 3 study showed that pegylated liposomal #doxorubicin significantly improved #PFS and #ORR in patients with progressive or symptomatic #desmoid tumors, supporting its potential as a new treatment option. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

🚨 The @US_FDA accepted the new drug application for #mezigdomide in combination with #carfilzomib and #dexamethasone for relapsed or refractory multiple #myeloma following positive phase 3 #SUCCESSOR2 results. Learn more: hmpgloballearningnetwork.com/site/onc/fda-a… #medtwitter #onctwitter

Ghassan Abou-Alfa, MD, PhD, discusses #EMERALD3 results evaluating #STRIDE-based #immunotherapy plsu #TACE in unresectable #HCC. Learn more: hmpgloballearningnetwork.com/site/onc/video…

Results from the phase 3 #KRYSTAL10 trial show #adagrasib plus #cetuximab did not significantly improve survival outcomes compared to standard #chemotherapy in previously treated KRAS G12C-mutated #mCRC. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

Guilherme Rabinowits, MD, discusses findings supporting #FID007 plus #cetuximab as a promising post-immunotherapy treatment strategy for recurrent or metastatic head and neck squamous cell carcinoma. Learn more: hubs.ly/Q04p9Jbd0

🚨 Breaking: The @US_FDA has approved perioperative pembrolizumab plus enfortumab vedotin for patients with muscle-invasive bladder cancer undergoing cystectomy based on results from the KEYNOTE-B15/EV-304 trial. Learn more: hmpgloballearningnetwork.com/site/onc/fda-a… #medtwitter #onctwitter

Results from the phase 3 #SENTRY trial: John Mascarenhas, MD, discusses updated findings supporting #selinexor plus #ruxolitinib as a promising frontline treatment strategy for patients with JAKi-naïve #myelofibrosis. Learn more: hmpgloballearningnetwork.com/site/onc/video… #medtwitter #onctwitter

🚨 Breaking: A new subcutaneous formulation of #isatuximab has received @US_FDA approval for 3 multiple #myeloma indications, offering an additional administration option across several established combination regimens. Learn more: hmpgloballearningnetwork.com/site/onc/fda-a… #medtwitter #onctwitter

Results from #CRSEQUENCE: @RamonSalazarS discusses phase 3 findings supporting first-line anti-EGFR therapy as the preferred biologic sequencing strategy for patients with #RAS wild-type, left-sided #mCRC. Learn more: hmpgloballearningnetwork.com/site/onc/video…

The @US_FDA has accepted the new drug application for #varegacestat for the treatment of adult patients with progressing desmoid tumors, supporting the investigational oral gamma secretase inhibitor as a potential new treatment option. Learn more: hmpgloballearningnetwork.com/site/onc/fda-a…

A qualitative study presented at the 2026 Oncology Nursing Society (ONS) Congress explored how patients receiving radiation therapy interpret these commonly used clinical concepts. Learn more: hubs.ly/Q04p116-0 #ONSCongress2026

Updated #ASTRUM005 results: #Serplulimab plus #carboplatin and #etoposide continues to improve long-term survival in previously untreated extensive-stage #SCLC. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

Results from the phase 2 #UNITED trial: MRI-guided adaptive #radiotherapy may safely reduce treatment margins while maintaining a low rate of marginal failure in adults with #glioblastoma. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

MRI-adapted #RECIST may outperform #RECIST 1.1 for assessing response after percutaneous #cryoablation in patients with progressing extra-abdominal #desmoid-type fibromatosis, according to a retrospective study. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

Results from #OrigAMI1: Paul Oberstein, MD, discusses updated findings which support #amivantamab monotherapy as a promising therapeutic strategy in refractory #mCRC. Learn more: hmpgloballearningnetwork.com/site/onc/video…

Adding #venetoclax to a fludarabine/melphalan conditioning regimen before #alloHSCT produced encouraging survival outcomes in older adults with #AML or #MDS in a phase 2 study. Learn more: hmpgloballearningnetwork.com/site/onc/news/…

Results from a real-world cohort study showed that first-line #chemoimmunotherapy significantly improved survival in extensive-stage #SCLC. Learn more: hmpgloballearningnetwork.com/site/onc/news/…